Loading…
Lipocine Inc. is projected to rise to $2.79 by 2027, a +32% move from its current price of $2.11. LPCN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $2.06 | $2.11 | $2.16 | +0.04% |
| Aug 6 | $2.04 | $2.11 | $2.19 | +0.08% |
| Aug 7 | $2.02 | $2.11 | $2.20 | +0.11% |
| Aug 8 | $2.01 | $2.11 | $2.22 | +0.15% |
| Aug 9 | $2.00 | $2.11 | $2.23 | +0.19% |
| Aug 10 | $1.99 | $2.11 | $2.25 | +0.23% |
| Aug 11 | $1.98 | $2.12 | $2.26 | +0.27% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.98 | $2.12 | $2.26 | +0.27% |
| Week 2 | $1.93 | $2.12 | $2.33 | +0.53% |
| Week 3 | $1.90 | $2.13 | $2.38 | +0.80% |
| Week 4 | $1.87 | $2.13 | $2.43 | +1.07% |
| Week 5 | $1.85 | $2.14 | $2.47 | +1.33% |
| Week 6 | $1.83 | $2.14 | $2.51 | +1.60% |
| Week 7 | $1.81 | $2.15 | $2.55 | +1.87% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Lipocine Inc. is a clinical-stage biopharmaceutical company focused on research and development for the delivery of drugs using its proprietary delivery technology. The company’s products focus on neurological and psychiatric central nervous system (CNS) disorders, liver disease, and hormone supplementation in the United States, and it engages in developing and delivering medicines across multiple programs.
It offers TLANDO, an oral testosterone replacement therapy comprising testosterone undecanoate, and it is advancing a portfolio including LPCN 1154 (BRLIZIO) for postpartum depression, LPCN 1148, LPCN 1107, LPCN 1144, LPCN 2401, and other candidates across various trial phases. Lipocine has collaborations such as with Verity Pharmaceuticals, Inc. to develop TLANDO and TLANDO XR (LPCN 1111).
The company was founded in 1997 and is headquartered in Salt Lake City, Utah.
Lipocine Inc. trades as LPCN. The current price is $2.08 with a market cap of $17.15M, and the stock is ranked 4699. The stock’s near‑term technical picture is neutral and the RSI14 sits at 40.
The 50‑day simple moving average is $2.30 and the 200‑day simple moving average is $4.62. A nearby support level is $1.98 and resistance is $2.56, with a 30‑day price range of $1.76 to $2.46. Annualized volatility stands at 50%.
The long‑term outlook shows a bullish trajectory, with 2026–2050 forecasts depicting rising averages and sizable ROIs, including a 2030 average of $4.00 and a 2050 average of $21.91, along with corresponding ROIs up to 953.5% by 2050.
A major floor 16.6% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.9% away) — a key level to hold.
The nearest ceiling, 21.3% above — a clean break opens room to run.
A major ceiling 338.4% above — clearing it would confirm fresh momentum.
Key LPCN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of LPCN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.12 | Sell | $2.12 | Sell |
| MA 10 | $2.14 | Sell | $2.16 | Sell |
| MA 20 | $2.26 | Sell | $2.22 | Sell |
| MA 50 | $2.28 | Sell | $2.47 | Sell |
| MA 100 | $3.21 | Sell | $3.19 | Sell |
| MA 200 | $4.59 | Sell | $3.84 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 40.49 | Neutral |
| Stoch RSI (14) | 41.88 | Neutral |
| CCI (20) | -76.99 | Neutral |
| Williams %R (14) | -82.76 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -10.17 | Sell |
| Bollinger %B (20,2) | 0.24 | Neutral |
| Stochastic %K (14) | 17.24 | Buy |
| TRIX (15) | -0.30 | Sell |
| Awesome (5,34) | -0.20 | Sell |
| Ultimate (7,14,28) | 35.14 | Neutral |
| Momentum (10) | -0.11 | Sell |
| Aroon Osc (25) | -80.00 | Sell |
| Hull MA (9) | 2.09 | Buy |
| ADX (14) | 17.46 | Neutral |
| ATR (14) | 0.05 | Info |
The 30-day technical picture is neutral. The RSI14 is 40, indicating a lukewarm momentum. The price is currently $2.08 and sits below the 50-day moving average of $2.30, and well below the 200-day moving average of $4.62. The stock trades within a 30‑day range of $1.76 to $2.46, with support at $1.98 and resistance at $2.56.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.94 | $2.11 | $2.72 | 0% | Neutral | |
| $2.25 | $2.79 | $3.65 | +32% | Bullish | |
| $2.79 | $3.55 | $4.81 | +68% | Bullish | |
| $2.96 | $3.85 | $5.36 | +83% | Bullish | |
| $3.02 | $4.00 | $5.70 | +90% | Bullish | |
| $3.44 | $4.63 | $6.73 | +120% | Bullish | |
| $3.57 | $4.88 | $7.22 | +131% | Bullish | |
| $4.08 | $5.67 | $8.51 | +169% | Bullish | |
| $5.09 | $7.16 | $10.92 | +240% | Bullish | |
| $5.29 | $7.53 | $11.63 | +257% | Bullish | |
| $7.98 | $12.07 | $19.74 | +472% | Bullish | |
| $13.29 | $22.19 | $39.48 | +952% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.94 | $2.11 | $2.51 | +0.00% |
| September 2026 | $1.78 | $2.10 | $2.54 | -0.42% |
| October 2026 | $1.84 | $2.18 | $2.67 | +3.95% |
| November 2026 | $1.86 | $2.22 | $2.73 | +1.61% |
| December 2026 | $1.83 | $2.19 | $2.72 | -1.14% |
Click any year to see its month-by-month LPCN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, LPCN could reach as high as $2.72, with a base case around $2.11 and support toward $1.94 — roughly 0% from $2.11. Price action looks broadly range-bound.
Expect LPCN to range from $2.25 to $3.65 through 2027. The $2.79 average target implies a +32% move from current prices. That is up +32% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The LPCN price prediction for 2028 points to an average of $3.55 (low $2.79, high $4.81) — a potential gain of +68% on today's $2.11. Momentum favours further upside here.
In 2029, LPCN is projected to trade between $2.96 and $5.36, averaging $3.85 — a potential gain of +83% from today's $2.11. That is up +9% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Lipocine Inc.'s 2030 outlook centres on $4.00, within a $3.02 to $5.70 range. That is up +4% on the projected 2029 average. That marks a +90% change versus current levels. Momentum favours further upside here.
By 2031, LPCN could reach as high as $6.73, with a base case around $4.63 and support toward $3.44 — roughly +120% from $2.11. Buyers look set to stay in control over this stretch.
Expect LPCN to range from $3.57 to $7.22 through 2032. The $4.88 average target implies a +131% move from current prices. That is up +5% on the projected 2031 average. Momentum favours further upside here.
The LPCN price prediction for 2033 points to an average of $5.67 (low $4.08, high $8.51) — a potential gain of +169% on today's $2.11. Buyers look set to stay in control over this stretch.
In 2034, LPCN is projected to trade between $5.09 and $10.92, averaging $7.16 — a potential gain of +240% from today's $2.11. That is up +26% on the projected 2033 average. Momentum favours further upside here.
Lipocine Inc.'s 2035 outlook centres on $7.53, within a $5.29 to $11.63 range. That is up +5% on the projected 2034 average. That marks a +257% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, LPCN could reach as high as $19.74, with a base case around $12.07 and support toward $7.98 — roughly +472% from $2.11. Momentum favours further upside here.
Expect LPCN to range from $13.29 to $39.48 through 2050. The $22.19 average target implies a +952% move from current prices. That is up +84% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in LPCN today (≈ 473.933649 LPCN) could be worth
$10,515.43
+$9,515.43 (+952%) by 2050 · US Dollar
Based on the average projected LPCN price of $22.19 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in LPCNwould be worth at today's price.
$1,000 invested in LPCN on Jul 31, 2025 (≈ 309.597521 LPCN) would be worth
$653.25
-$346.75 (-34.7%) today · 0.65× · US Dollar
Based on a LPCN entry price of $3.23 vs. today's $2.11.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.08 | $1,014.42 | +1.4% |
| 1 month ago | $2.46 | $857.72 | -14.2% |
| 3 months ago | $2.33 | $905.58 | -9.4% |
| 6 months ago | $9.01 | $234.18 | -76.6% |
| 1 year ago | $3.23 | $653.25 | -34.7% |
| All time (5.0y) ago | $22.44 | $94.03 | -90.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our LPCN forecast.
Our base-case forecast reaches $4.20 around 2031.
Implied market cap at $4.20: $34.63M
The multi-year forecast shows growing investor interest and upside across the horizon. The 2026 forecast places Lipocine at an average of $2.08 with a 0% ROI, followed by a bullish arc: 2027 average $2.82 (ROI 35.4%), 2028 average $3.49 (ROI 68%), 2029 average $3.80 (ROI 82.7%), and 2030 average $4.00 (ROI 92.3%). The trajectory continues higher in later years, with 2031 average $4.56 (ROI 119%), 2032 $4.82 (ROI 131.9%), 2033 $5.65 (ROI 171.6%), 2034 $7.08 (ROI 240.2%), and 2035 $7.48 (ROI 259.6%).
By 2040, the average is $11.92 (ROI 472.9%), and by 2050 the average reaches $21.91 (ROI 953.5%). The forecasts carry bullish sentiment across 2027 through 2050, with higher expected prices and substantial upside, while noting that these are estimates and not guarantees.
Tap a question to reveal the answer.
2030 avg $4.00, min $3.01, max $5.72; ROI 92.3%; sentiment BULLISH.
The forecast shows a bullish trajectory from 2027 onward, with 2027 avg $2.82 (ROI 35.4%), 2028 avg $3.49 (ROI 68%), 2029 avg $3.80 (ROI 82.7%), and 2030 avg $4.00 (ROI 92.3%). Longer-horizon ROIs rise to 119% (2031), 131.9% (2032), 171.6% (2033), 240.2% (2034), and 259.6% (2035), with 2040 at 472.9% and 2050 at 953.5%. These are estimates and not guarantees.
2034 max $10.85; 2035 max $11.63; 2040 max $19.65; 2050 max $39.37. This indicates the possibility of crossing $10 in the forecast window, with higher potential in later years.
Current price is $2.08. The 30-day range is $1.76 to $2.46.
2050 avg $21.91, min $12.96, max $39.37; ROI 953.5%; sentiment BULLISH.
Lipocine Inc. Community Discussion
0Share your Lipocine Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.